What is Supernus Pharma's earnings per share (EPS)?

Supernus Pharma (SUPN) reported diluted earnings per share of $-0.68 for fiscal year 2025. This represents a -151.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Supernus Pharma Financials

SUPN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Supernus Pharma (SUPN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 37/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Supernus Pharma has an operating margin of -8.7%, meaning the company retains $-9 of operating profit per $100 of revenue. This below-average margin results in a low score of 3/100, suggesting thin profitability after operating expenses. This is down from 12.3% the prior year.

Growth

Supernus Pharma's revenue grew 8.6% year-over-year to $719.0M, a solid pace of expansion. This earns a growth score of 48/100.

Leverage

Supernus Pharma carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Supernus Pharma's current ratio of 1.90 indicates adequate short-term liquidity, earning a score of 34/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Supernus Pharma has a free cash flow margin of 6.4%, earning a moderate score of 41/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Supernus Pharma generates a -3.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 3/100. This is down from 7.1% the prior year.

Piotroski F-Score Neutral

4/9

Supernus Pharma passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

-1.23x

For every $1 of reported earnings, Supernus Pharma generates $-1.23 in operating cash flow ($47.3M OCF vs -$38.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$719.0M

YoY+8.6%

5Y CAGR+6.7%

10Y CAGR+17.2%

Supernus Pharma generated $719.0M in revenue in fiscal year 2025. This represents an increase of 8.6% from the prior year.

EBITDA

$29.3M

YoY-81.9%

5Y CAGR-31.3%

10Y CAGR+3.0%

Supernus Pharma's EBITDA was $29.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 81.9% from the prior year.

Net Income

-$38.5M

YoY-152.2%

Supernus Pharma reported -$38.5M in net income in fiscal year 2025. This represents a decrease of 152.2% from the prior year.

EPS (Diluted)

$-0.68

YoY-151.5%

Supernus Pharma earned $-0.68 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 151.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$46.0M

YoY-73.1%

5Y CAGR-19.4%

10Y CAGR+3.6%

Supernus Pharma generated $46.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 73.1% from the prior year.

Cash & Debt

$128.4M

YoY+85.3%

5Y CAGR-15.0%

10Y CAGR+14.4%

Supernus Pharma held $128.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

57M

YoY+3.1%

5Y CAGR+1.7%

10Y CAGR+1.6%

Supernus Pharma had 57M shares outstanding in fiscal year 2025. This represents an increase of 3.1% from the prior year.

Margins & Returns

Gross Margin

89.6%

YoY+1.4pp

5Y CAGR-0.3pp

10Y CAGR-4.7pp

Supernus Pharma's gross margin was 89.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the prior year.

Operating Margin

-8.7%

YoY-21.0pp

5Y CAGR-42.0pp

10Y CAGR-22.8pp

Supernus Pharma's operating margin was -8.7% in fiscal year 2025, reflecting core business profitability. This is down 21.0 percentage points from the prior year.

Net Margin

-5.4%

YoY-16.5pp

5Y CAGR-29.8pp

10Y CAGR-14.8pp

Supernus Pharma's net profit margin was -5.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 16.5 percentage points from the prior year.

Return on Equity

-3.6%

YoY-10.8pp

5Y CAGR-20.7pp

10Y CAGR-19.5pp

Supernus Pharma's ROE was -3.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$106.2M

YoY-2.4%

5Y CAGR+6.9%

10Y CAGR+13.8%

Supernus Pharma invested $106.2M in research and development in fiscal year 2025. This represents a decrease of 2.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.3M

YoY+84.6%

5Y CAGR-17.3%

10Y CAGR-4.4%

Supernus Pharma invested $1.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 84.6% from the prior year.

SUPN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$719.0M+8.6%	$661.8M+8.9%	$607.5M-8.9%	$667.2M+15.1%	$579.8M+11.4%	$520.4M
Cost of Revenue	$74.6M-4.3%	$77.9M-7.0%	$83.8M-3.9%	$87.2M+16.2%	$75.1M+43.1%	$52.5M
Gross Profit	$644.4M+10.4%	$583.9M+11.5%	$523.7M-9.7%	$580.0M+14.9%	$504.7M+7.9%	$467.9M
R&D Expenses	$106.2M-2.4%	$108.8M+18.8%	$91.6M+22.9%	$74.6M-17.6%	$90.5M+19.1%	$76.0M
SG&A Expenses	$485.6M+51.0%	$321.6M-4.4%	$336.4M-10.8%	$377.2M+23.8%	$304.8M+51.9%	$200.7M
Operating Income	-$62.3M-176.3%	$81.7M+1649.9%	-$5.3M-111.4%	$46.1M-46.4%	$86.0M-50.5%	$173.7M
Interest Expense	$0	$0-100.0%	$1.3M-48.0%	$2.5M-87.1%	$19.7M+1.3%	$19.4M
Income Tax	-$10.5M-143.7%	$24.0M+1552.1%	$1.5M+4440.6%	$32K-99.8%	$19.8M-52.6%	$41.7M
Net Income	-$38.5M-152.2%	$73.9M+5512.8%	$1.3M-97.8%	$60.7M+13.6%	$53.4M-57.9%	$127.0M
EPS (Diluted)	$-0.68-151.5%	$1.32+6500.0%	$0.02-98.1%	$1.04+6.1%	$0.98-58.5%	$2.36

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$211.6M+10.1%	$192.1M+16.1%	$165.5M+10.4%	$149.8M-14.0%	$174.2M-0.9%	$175.7M+4.4%	$168.3M+17.2%	$143.6M
Cost of Revenue	$23.0M+21.3%	$19.0M+12.7%	$16.8M+6.7%	$15.8M-39.6%	$26.1M+48.4%	$17.6M-1.9%	$17.9M+9.9%	$16.3M
Gross Profit	$188.6M+8.9%	$173.1M+16.5%	$148.6M+10.9%	$134.1M-9.5%	$148.1M-6.4%	$158.1M+5.1%	$150.4M+18.1%	$127.3M
R&D Expenses	$27.8M-5.2%	$29.4M+32.8%	$22.1M-17.9%	$26.9M-6.0%	$28.6M-1.3%	$29.0M+10.9%	$26.2M+5.0%	$24.9M
SG&A Expenses	$122.4M-31.9%	$179.7M+92.1%	$93.6M+4.0%	$89.9M+13.3%	$79.4M+13.8%	$69.8M-18.8%	$85.9M-0.7%	$86.5M
Operating Income	-$3.9M+93.5%	-$60.2M-596.1%	$12.1M+218.4%	-$10.3M-147.9%	$21.4M-47.6%	$40.8M+81.0%	$22.6M+815.8%	-$3.2M
Interest Expense	N/A	N/A	N/A	N/A	$0	$0	$0	$0
Income Tax	$2.2M+117.1%	-$12.8M-120.2%	-$5.8M-197.2%	$6.0M-45.8%	$11.1M+71.5%	$6.4M+0.9%	$6.4M+5266.4%	$119K
Net Income	-$4.1M+90.9%	-$45.1M-300.5%	$22.5M+290.2%	-$11.8M-177.2%	$15.3M-60.2%	$38.5M+93.3%	$19.9M+15961.3%	$124K
EPS (Diluted)	N/A	$-0.80-300.0%	$0.40+290.5%	$-0.21	N/A	$0.69+91.7%	$0.36	$0.00

SUPN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.5B+6.2%	$1.4B+7.1%	$1.3B-25.0%	$1.7B+0.8%	$1.7B+12.3%	$1.5B
Current Assets	$644.2M-6.1%	$686.1M+39.1%	$493.1M-32.8%	$734.2M+22.0%	$601.6M-4.6%	$630.4M
Cash & Equivalents	$128.4M+85.3%	$69.3M-7.6%	$75.1M-19.4%	$93.1M-54.2%	$203.4M-29.5%	$288.6M
Inventory	$112.5M+107.2%	$54.3M-29.9%	$77.4M-15.4%	$91.5M+6.5%	$86.0M+77.9%	$48.3M
Accounts Receivable	$187.8M+32.2%	$142.1M-1.4%	$144.2M-12.9%	$165.5M+11.1%	$148.9M+5.7%	$140.9M
Goodwill	$124.9M+6.7%	$117.0M0.0%	$117.0M0.0%	$117.0M-0.4%	$117.5M+50.8%	$77.9M
Total Liabilities	$390.9M+17.6%	$332.3M-6.7%	$356.2M-56.4%	$816.3M-6.5%	$873.3M+15.0%	$759.2M
Current Liabilities	$338.2M+15.7%	$292.4M+0.8%	$290.2M-57.8%	$688.0M+118.1%	$315.4M+28.7%	$245.1M
Long-Term Debt	N/A	N/A	N/A	N/A	$379.3M	N/A
Total Equity	$1.1B+2.5%	$1.0B+12.4%	$921.5M+4.0%	$886.2M+8.6%	$815.9M+9.5%	$744.9M
Retained Earnings	$517.9M-6.9%	$556.4M+15.3%	$482.6M+0.3%	$481.2M+26.7%	$379.9M+16.4%	$326.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.5B+2.3%	$1.4B+2.7%	$1.4B+2.6%	$1.3B-1.5%	$1.4B+1.9%	$1.3B+2.0%	$1.3B+0.9%	$1.3B
Current Assets	$644.2M+8.5%	$593.9M-19.6%	$738.9M+7.5%	$687.6M+0.2%	$686.1M+7.2%	$640.0M+8.3%	$591.0M+8.6%	$544.3M
Cash & Equivalents	$128.4M-15.1%	$151.4M+4.6%	$144.7M+24.9%	$115.8M+67.1%	$69.3M+118.9%	$31.7M-39.2%	$52.1M-17.8%	$63.4M
Inventory	$112.5M+5.0%	$107.1M+143.3%	$44.0M-10.9%	$49.4M-9.0%	$54.3M-15.1%	$64.0M-6.1%	$68.2M-9.2%	$75.1M
Accounts Receivable	$187.8M+9.7%	$171.3M+21.6%	$140.8M-3.3%	$145.6M+2.5%	$142.1M-2.3%	$145.4M-4.6%	$152.5M+3.2%	$147.7M
Goodwill	$124.9M+4.9%	$119.1M+1.8%	$117.0M0.0%	$117.0M0.0%	$117.0M0.0%	$117.0M0.0%	$117.0M0.0%	$117.0M
Total Liabilities	$390.9M+5.6%	$370.1M+16.2%	$318.5M+0.6%	$316.6M-4.7%	$332.3M-1.0%	$335.6M-6.4%	$358.4M-4.4%	$374.9M
Current Liabilities	$338.2M+2.3%	$330.6M+15.5%	$286.4M+1.6%	$281.8M-3.6%	$292.4M+0.3%	$291.5M-5.6%	$308.7M-1.9%	$314.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.1B+1.1%	$1.0B-1.3%	$1.1B+3.2%	$1.0B-0.5%	$1.0B+2.8%	$1.0B+5.2%	$957.5M+3.0%	$929.2M
Retained Earnings	$517.9M-0.8%	$522.0M-8.0%	$567.1M+4.1%	$544.6M-2.1%	$556.4M+2.8%	$541.1M+7.7%	$502.6M+4.1%	$482.7M

SUPN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$47.3M-72.5%	$172.0M+54.8%	$111.1M-4.9%	$116.8M-8.1%	$127.1M-8.1%	$138.4M
Capital Expenditures	$1.3M+84.6%	$725K+31.6%	$551K+33.7%	$412K	N/A	$3.4M
Free Cash Flow	$46.0M-73.1%	$171.2M+54.9%	$110.5M-5.1%	$116.4M	N/A	$134.9M
Investing Cash Flow	$4.1M+102.2%	-$189.9M-170.7%	$268.7M+224.0%	-$216.7M-164.5%	-$81.9M-136.1%	-$34.7M
Financing Cash Flow	$9.1M-25.1%	$12.2M+103.1%	-$397.9M-3697.7%	-$10.5M+92.0%	-$130.4M-3764.5%	$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$19.9M+132.2%	-$61.7M-205.3%	$58.5M+91.3%	$30.6M-31.1%	$44.4M-17.0%	$53.5M+50.2%	$35.6M-7.2%	$38.4M
Capital Expenditures	$427K+231.0%	$129K-71.6%	$455K+39.1%	$327K+53.5%	$213K+6.5%	$200K+212.5%	$64K-74.2%	$248K
Free Cash Flow	$19.4M+131.5%	-$61.8M-206.4%	$58.1M+91.9%	$30.3M-31.5%	$44.2M-17.1%	$53.3M+49.9%	$35.6M-6.8%	$38.2M
Investing Cash Flow	-$51.3M-205.3%	$48.7M+259.1%	-$30.6M-182.0%	$37.3M+395.3%	-$12.6M+83.6%	-$77.0M-58.5%	-$48.6M+5.9%	-$51.6M
Financing Cash Flow	$8.5M-59.5%	$21.1M+2153.3%	$935K+104.4%	-$21.4M-463.3%	$5.9M+91.5%	$3.1M+85.5%	$1.7M+5.6%	$1.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SUPN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	89.6%+1.4pp	88.2%+2.0pp	86.2%-0.7pp	86.9%-0.1pp	87.1%-2.9pp	89.9%
Operating Margin	-8.7%-21.0pp	12.3%+13.2pp	-0.9%-7.8pp	6.9%-7.9pp	14.8%-18.5pp	33.4%
Net Margin	-5.4%-16.5pp	11.2%+10.9pp	0.2%-8.9pp	9.1%-0.1pp	9.2%-15.2pp	24.4%
Return on Equity	-3.6%-10.8pp	7.1%+7.0pp	0.1%-6.7pp	6.9%+0.3pp	6.6%-10.5pp	17.0%
Return on Assets	-2.6%-8.1pp	5.4%+5.3pp	0.1%-3.5pp	3.6%+0.4pp	3.2%-5.3pp	8.4%
Current Ratio	1.90-0.4	2.35+0.6	1.70+0.6	1.07-0.8	1.91-0.7	2.57
Debt-to-Equity	0.37+0.0	0.32-0.1	0.39-0.5	0.92+0.5	0.46-0.6	1.02
FCF Margin	6.4%-19.5pp	25.9%+7.7pp	18.2%+0.7pp	17.4%	N/A	25.9%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	89.1%-1.0pp	90.1%+0.3pp	89.8%+0.3pp	89.5%+4.5pp	85.0%-5.0pp	90.0%+0.6pp	89.4%+0.7pp	88.6%
Operating Margin	-1.9%+29.5pp	-31.4%-38.7pp	7.3%+14.2pp	-6.9%-19.1pp	12.3%-11.0pp	23.3%+9.8pp	13.4%+15.6pp	-2.2%
Net Margin	-1.9%+21.6pp	-23.5%-37.1pp	13.6%+21.5pp	-7.9%-16.7pp	8.8%-13.1pp	21.9%+10.1pp	11.8%+11.7pp	0.1%
Return on Equity	-0.4%+3.9pp	-4.3%-6.4pp	2.1%+3.3pp	-1.1%-2.6pp	1.5%-2.3pp	3.8%+1.7pp	2.1%+2.1pp	0.0%
Return on Assets	-0.3%+2.9pp	-3.2%-4.8pp	1.6%+2.5pp	-0.9%-2.0pp	1.1%-1.8pp	2.9%+1.4pp	1.5%+1.5pp	0.0%
Current Ratio	1.90+0.1	1.80-0.8	2.58+0.1	2.44+0.1	2.35+0.2	2.20+0.3	1.91+0.2	1.73
Debt-to-Equity	0.37+0.0	0.35+0.1	0.300.0	0.31-0.0	0.32-0.0	0.33-0.0	0.37-0.0	0.40
FCF Margin	9.2%+41.4pp	-32.2%-67.3pp	35.1%+14.9pp	20.2%-5.2pp	25.4%-5.0pp	30.3%+9.2pp	21.1%-5.4pp	26.6%

Similar Companies

Alvotech ALVO

$1.1B

Indivior Pharmaceuticals Inc. INDV

$3.7B

Kiniksa Pharmaceuticals International, plc KNSA

$3.7B

Bausch Health Companies Inc BHC

$2.0B

Hutchmed (China) Limited HCM

$2.7B

Frequently Asked Questions

What is Supernus Pharma's annual revenue?

Supernus Pharma (SUPN) reported $719.0M in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Supernus Pharma's revenue growing?

Supernus Pharma (SUPN) revenue grew by 8.6% year-over-year, from $661.8M to $719.0M in fiscal year 2025.

Is Supernus Pharma profitable?

No, Supernus Pharma (SUPN) reported a net income of -$38.5M in fiscal year 2025, with a net profit margin of -5.4%.

What is Supernus Pharma's EBITDA?

Supernus Pharma (SUPN) had EBITDA of $29.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Supernus Pharma's gross margin?

Supernus Pharma (SUPN) had a gross margin of 89.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Supernus Pharma's operating margin?

Supernus Pharma (SUPN) had an operating margin of -8.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Supernus Pharma's net profit margin?

Supernus Pharma (SUPN) had a net profit margin of -5.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Supernus Pharma's return on equity (ROE)?

Supernus Pharma (SUPN) has a return on equity of -3.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Supernus Pharma's free cash flow?

Supernus Pharma (SUPN) generated $46.0M in free cash flow during fiscal year 2025. This represents a -73.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Supernus Pharma's operating cash flow?

Supernus Pharma (SUPN) generated $47.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Supernus Pharma's total assets?

Supernus Pharma (SUPN) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Supernus Pharma's capital expenditures?

Supernus Pharma (SUPN) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Supernus Pharma spend on research and development?

Supernus Pharma (SUPN) invested $106.2M in research and development during fiscal year 2025.

How many shares does Supernus Pharma have outstanding?

Supernus Pharma (SUPN) had 57M shares outstanding as of fiscal year 2025.

What is Supernus Pharma's current ratio?

Supernus Pharma (SUPN) had a current ratio of 1.90 as of fiscal year 2025, which is generally considered healthy.

What is Supernus Pharma's debt-to-equity ratio?

Supernus Pharma (SUPN) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Supernus Pharma's return on assets (ROA)?

Supernus Pharma (SUPN) had a return on assets of -2.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Supernus Pharma's Piotroski F-Score?

Supernus Pharma (SUPN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Supernus Pharma's earnings high quality?

Supernus Pharma (SUPN) has an earnings quality ratio of -1.23x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Supernus Pharma?

Supernus Pharma (SUPN) scores 37 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.